Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Cost of goods sold | 282,684 | 48,265 | 130,740 | — | 461,689 |
| Gross profit | 207,229 | 101,030 | 26,249 | — | 334,508 |
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — R&D?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — R&D of $0 in Q2 2026.
- What does avkare — R&D mean?
- Represents expenditures incurred by the AvKARE segment to discover, develop, and improve pharmaceutical products or delivery systems. This metric indicates the segment's commitment to long-term innovation and its pipeline potential for future revenue streams.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude